Bavarian Nordic A/S/ DK0015998017 /
2024-04-04 4:46:41 PM | Chg. - | Volume | Bid9:00:00 AM | Ask9:00:00 AM | High | Low |
---|---|---|---|---|---|---|
156.90DKK | - | 500 Turnover: 78,450 |
-Bid Size: - | -Ask Size: - | 156.90 | 156.90 |
GlobeNewswire
03-20
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire
02-23
Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire
2023-11-09
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2023-09-21
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
2022-03-21
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire
2022-02-28
Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire
2022-02-14
Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire
2022-02-03
Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
GlobeNewswire
2021-12-06
Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...
GlobeNewswire
2021-12-05
Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
GlobeNewswire
2021-09-01
Bavarian Nordic Reports Positive Results from Human Challenge Trial of its RSV Vaccine Candidate